3.3 Risk factors associated with 14-day IMV rates in Flu-p patients
Next, univariate analyses were conducted which identified age ≥ 65 years old, influenza A virus infection, the presence of solid malignant tumors, a respiratory rate ≥ 30 breaths/min, a leukocyte count > 10×109/L, ALB < 35 g/L, arterial PH < 7.35, PaO2/FiO2< 300 mmHg, early NAI therapy, and systemic corticosteroids use before IMV to be associated with 14-day IMV rates in Flu-p patients (Table 1).
In a subsequent multivariate logistic regression model, factors that were identified as independent predictors of a higher risk of requiring IMV in Flu-p patients (Figure 2) included: early NAI use (OR0.041, 95% CI 0.005-0.171, p = 0.004; -2 points), lymphocytes < 0.8×109/L (OR 6.081,95% CI 2.414-15.318, p < 0.001; 1 point), multilobar infiltrates (OR 4.515, 95% CI 1.182-17.249,p = 0.028; 1 point), age ≥ 65 years old (OR 10.941,95% CI 3.917-30.561, p < 0.001; 2 points), systemic corticosteroid administration (OR 10.787, 95% CI3.124-37.245, p < 0.001; 2 points), PaO2/FiO2 < 300 mmHg (OR 14.015, 95% CI 4.829-40.673, p < 0.001; 2 points), respiratory rate ≥ 30 breaths/min (OR 57.766,95% CI 19.365-172.316, p < 0.001; 3 points), and arterial PH < 7.35 (OR 64.887, 95% CI7.476-132.174, p < 0.001; 3 points).